Azido-PEG4-Val-Cit-PAB-OH
Based on 1 Customer Validation
Azido-PEG4-Val-Cit-PAB-OH is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG4-Val-Cit-PAB-OH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Azido-PEG4-Val-Cit-PAB-OH is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
For research use only. We do not sell to patients.
- Purity : 95.09%
- CAS No.: 2055024-64-9
- Formula: C29H48N8O9
- Molecular Weight:652.74
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-140150
Azido-PEG3-Val-Cit-PAB-PNPADC Linker -
HY-20336
Mc-Val-Cit-PABC-PNPADC Linker -
HY-12362
Val-cit-PAB-OHADC Linker -
HY-41189
Fmoc-Val-Cit-PAB-PNPADC Linker -
HY-78738
MC-Val-Cit-PABADC Linker -
HY-19318
Fmoc-Val-Cit-PABADC Linker -
HY-141142
Boc-Val-Cit-PAB-PNPADC Linker -
HY-140145
Mal-PEG4-Val-Cit-PAB-PNPADC linker -
HY-141141
Boc-Val-Cit-PABADC Linker -
HY-W038702
Boc-Val-Cit-OH -
HY-130944
Mal-PEG1-Val-Cit-PABC-OHADC Linker -
HY-140144
Mal-PEG1-Val-Cit-PAB-PNPADC Linker
All PROTAC Linkers Isoforms
More
Biological Activity
Description
|
Protease Cleavable Linker |
PEGs |
Cleavable Linker |
In Vitro
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 2055024-64-9
-
Appearance Solid
-
Molecular Weight 652.74
-
Formula C29H48N8O9
-
Color White to off-white
-
SMILES
O=C(N)[C@H](CCCNC(N)=O)N(C([C@H](C(C)C)NC(CCOCCOCCOCCOCCN=[N+]=[N-])=O)=O)C1=CC=C(CO)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
Purity & Documentation
-
Data Sheet (266 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Dan N, et al. Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. Pharmaceuticals (Basel). 2018 Apr 9;11(2). pii: E32. [Content Brief]
[2]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Azido-PEG4-Val-Cit-PAB-OH Related Classifications
HY-140149 Related Classifications
Powered by Bioz